Gene therapy is a critical tool for the treatment of monogenic retinal diseases. However, the limited vector capacity of the current benchmark delivery strategy, adeno-associated virus (AAV), makes development of larger capacity alternatives, such as compacted DNA nanoparticles (NPs), critical. Here we conduct a side-by-side comparison of self-complementary AAV and CK30PEG NPs using matched ITR plasmids. We report that although AAVs are more efficient per vector genome (vg) than NPs, NPs can drive gene expression on a comparable scale and longevity to AAV. We show that subretinally injected NPs do not leave the eye while some of the AAV-injected animals exhibited vector DNA and GFP expression in the visual pathways of the brain from PI-60 onward. As a result, these NPs have the potential to become a successful alternative for ocular gene therapy, especially for the multitude of genes too large for AAV vectors. © 2012 Han et al.
CITATION STYLE
Han, Z., Conley, S. M., Makkia, R., Guo, J., Cooper, M. J., & Naash, M. I. (2012). Comparative Analysis of DNA Nanoparticles and AAVs for Ocular Gene Delivery. PLoS ONE, 7(12). https://doi.org/10.1371/journal.pone.0052189
Mendeley helps you to discover research relevant for your work.